These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36896583)

  • 21. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
    Gianotti N; Mondino V; Rossi MC; Chiesa E; Mezzaroma I; Ladisa N; Guaraldi G; Torti C; Tarquini P; Castelli P; Di Carlo A; Boeri E; Keulen W; Kenna PM; Lazzarin A;
    Clin Infect Dis; 2006 May; 42(10):1470-80. PubMed ID: 16619162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.
    Weiser SD; Guzman D; Riley ED; Clark R; Bangsberg DR
    HIV Clin Trials; 2004; 5(5):278-87. PubMed ID: 15562368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases.
    Ghani AC; Henley WE; Donnelly CA; Mayer S; Anderson RM
    AIDS; 2001 Jun; 15(9):1133-42. PubMed ID: 11416715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study.
    Viciana P; Ocampo A; Hevia H; Palazuelos M; Ledesma F
    AIDS Care; 2016 Oct; 28(10):1321-6. PubMed ID: 27140483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
    Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.
    Gardner EM; Hullsiek KH; Telzak EE; Sharma S; Peng G; Burman WJ; MacArthur RD; Chesney M; Friedland G; Mannheimer SB;
    AIDS; 2010 Jan; 24(3):395-403. PubMed ID: 20099399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.